Compare Amylx Pharmaceuticals Inc (AMLX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B), while Norwegian Cruise Line Holdings Ltd trades at $18.92 (market cap $8.59B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3.3× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | NCLH | |
|---|---|---|
Market Cap | $2.64B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $26.94 |
52-Week Low | $7.82 | $14.79 |
Enterprise Value | $2.39B | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
NCLH trades at $19.09, up 2.91% today, with a bearish technical signal but recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding the $0.4115 estimate, and revenue growth has improved from $4.8B in 2022 to $9.83B in 2025. However, net income margin declined to 4.3% in 2025 from 9.6% in 2024, and high debt levels remain a concern with total liabilities of $18.54B against equity of $1.43B.
The outlook is mixed: analyst consensus is a Buy with a $20.73 price target, but risks include volatile fuel costs, macroeconomic pressures on travel demand, and execution of turnaround plans. The stock offers value with a P/E of 11.33, yet investor sentiment is cautious due to recent guidance cuts and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
